Docket No.

239637US8

TEND TRADEMARK OFFICE IN THE UNITED STATES P.

IN RE APPLICATION OF:

Thomas NILSSON, et al

SERIAL NO:

10/603,818

FILED:

June 26, 2003

FOR:

COMBINED DOSES

GAU:

1616

EXAMINER: Unassigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449 which were cited in an International Search Report for International Application No. PCT/SE2004/000953. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

well

Bradley D. Lytle

Registration No. 40,073

Customer Number

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

NOV 1 2 2004

SHEET

OF

					<u> </u>	\&/ ¬				
Form PTO 1449		U.S. DEPARTMENT OF COMMERCE		ATTY DOCKET NO.	TRADE!	<u> </u>	SERIAL N			
(Modified) PATENT AND TRADEMARK OFFICE			239637US8	10/603,818						
				APPLICANT						
LIST OF I	REFER	ENCES CITED BY APPL	ICANT	Thomas NILSSON, et al.						
				FILING DATE			GROUP ·			
				June 26, 2003			1616			
				J.S. PATENT DOCUME	NTS					
		DOCUMENT		SUB FILING DATE						
EXAMINER I		DOCUMENT NUMBER	DATE	NAME		CLASS	CLASS	IF APPF	OPRIATE	
	AA	5.901.883 5	-11-99	RITSCHE						
	AB	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,								
	AC									
	AD									
	AE									
	AF									
	AG					-				
	AH									
	Al						† †			
	AJ						+			
	AK	ļ				<u> </u>	-	 		
	AL					 	+			
<u> </u>	AM						 			
	AN	<u> </u>				L		<u> </u>		
			FC	REIGN PATENT DOCU	MENTS					
	DOCUMENT DATE COUNTRY TRANSLATIO							TION		
		NUMBER	DATE	COUNTRY			YES NO		NO	
	AO	WO 03/061743	7-31-03	WIPO			×			
	AP		9-25-03	WIPO			x			
	AQ		2-14-02	WIPO			×			
<u> </u>	AR	WO 01/76601	10-18-01	WIPO			X			
	AS	WO 00/64520	11-2-00	WIPO			X			
			4-9-03	European			×			
	AT	EP 1300171 WO 02/085281	10-31-02	WIPO			×			
<u> </u>	AU		11-2-00	WIPO			×			
ļ	AV	WO 00/64519	10-25-01	WIPO			×			
	AW			WIPO			×			
<u> </u>	AX		3-28-02		D. A. Dartina		oto)	L		
		OTHER RE	FERENCES	(Including Author, Titl	e, Date, Pertiner	nt Pages,	- Description	- (50/100 u	a) in	
	Τ	Pediatric Pulmonology	, Vol. 30, 20	00, N.J. Van den Berg et	al, "Salmeterol/⊢ ive and Safe in C	luticason hildren W	e Propionat 'ith Asthma'	e (50/100 d ', pages 97	-105	
1	Pediatric Pulmonology, Vol. 30, 2000, N.J. Van den Berg et al, Saintetelov Indiated With Asthma", pages 97-105 AY Combination in a Diskus TM Inhaler (Seretide TM) Is Effective and Safe in Children With Asthma", pages 97-105									
	<u> </u>	European Respiratory Journal, Vol. 2, suppl. 28, 1998, M. Ringdal et al, "Asthma control with salmeterol and fluticasone propionate (50/250 u.g) Given twice daily in a single combination diskus (accuhalar) inhaler compared to salmeterol, 50 ug propionate (50/250 u.g) Given twice daily in a single combination diskus (accuhalar) inhaler compared to salmeterol, 50 ug								
	AZ	AZ propionate (50/250 u.g) Given twice daily in a single combination districts (described and propionate (50/250 u.g.) Given twice daily in a single combination districts (described and propionate (50/250 u.g.) Given twice daily in a single combination districts (described and propionate (50/250 u.g.) Given twice daily in a single combination districts (described and propionate (50/250 u.g.) Given twice daily in a single combination districts (described and propionate (50/250 u.g.) Given twice daily in a single combination districts (described and propionate (50/250 u.g.) Given twice daily in a single combination districts (described and propionate (50/250 u.g.) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice daily in a single combination districts (described and propionate (50/250 u.g.)) Given twice (50/250 u.g.) Given t								
	 	European Respiratory Journal, Vol 12, suppl. 28, 1998, N.J. van den beig et al, Combined del Modern School de la fluticasone propionate (50/100 ug strength) BD via one diskus (accuhaler) inhaler compared with salmeterol xinafoate 50 ug and fluticasone propionate 100 ug BD via two separate diskus inhalers", page 157s, column P1108								
	BA									
		I Polivery of Invatronium and Albuterol Combination Therapy for Chronic								
	ВВ	Obstructive Pulmonary Disease: Effectiveness of a Two-in-one Inhaler Versus Separate Inhalers", The American Journal of Managed Care, Vol. 8,							.con(o) andonoa	
		October 2002, Elizabe	eth Chrischille	es et al, pages 902-911.						
Examiner Date Considered										
			1		ance with MPEP	609: Drav	w line through	n citation in	f not in	
*Examiner:	: Initial i	if reference is considered not considered. Include of	, wnetner or copy of this fo	not citation is in comornication with next communication.	ition to applicant.	,				